These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15134533)

  • 1. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions.
    Rooney PH; Telfer C; McFadyen MC; Melvin WT; Murray GI
    Curr Cancer Drug Targets; 2004 May; 4(3):257-65. PubMed ID: 15134533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
    Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
    Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochromes P450 in the bioactivation of chemicals.
    Ioannides C; Lewis DF
    Curr Top Med Chem; 2004; 4(16):1767-88. PubMed ID: 15579107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome p450 and chemical toxicology.
    Guengerich FP
    Chem Res Toxicol; 2008 Jan; 21(1):70-83. PubMed ID: 18052394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.
    Rendic SP; Guengerich FP
    Arch Toxicol; 2021 Feb; 95(2):395-472. PubMed ID: 33459808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s.
    Damsten MC; de Vlieger JS; Niessen WM; Irth H; Vermeulen NP; Commandeur JN
    Chem Res Toxicol; 2008 Nov; 21(11):2181-7. PubMed ID: 18816075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of different cytochrome P450 enzymes in bioactivation of the potent hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver microsomes.
    Yamazaki H; Degawa M; Funae Y; Imaoka S; Inui Y; Guengerich FP; Shimada T
    Carcinogenesis; 1991 Jan; 12(1):133-9. PubMed ID: 1988174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cytochrome P450 activity: implications for cancer therapy.
    Scripture CD; Sparreboom A; Figg WD
    Lancet Oncol; 2005 Oct; 6(10):780-9. PubMed ID: 16198984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites.
    Mueller SO; Stopper H; Dekant W
    Drug Metab Dispos; 1998 Jun; 26(6):540-6. PubMed ID: 9616189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
    Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
    Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues.
    Scarborough PE; Ma J; Qu W; Zeldin DC
    Drug Metab Rev; 1999 Feb; 31(1):205-34. PubMed ID: 10065373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
    McCarthy HO; Yakkundi A; McErlane V; Hughes CM; Keilty G; Murray M; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2003 Jan; 10(1):40-8. PubMed ID: 12489027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
    Jounaidi Y; Hecht JE; Waxman DJ
    Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.
    Murray M
    Clin Pharmacokinet; 1992 Aug; 23(2):132-46. PubMed ID: 1511529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.
    Pirmohamed M; Madden S; Park BK
    Clin Pharmacokinet; 1996 Sep; 31(3):215-30. PubMed ID: 8877251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1.
    Raucy JL; Kraner JC; Lasker JM
    Crit Rev Toxicol; 1993; 23(1):1-20. PubMed ID: 8471158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.